Select publications

Cassidy J et al. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22(11):2084-91. Abstract

Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22(1):23-30. Abstract

Grothey A et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as firstline therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003;1(5 Suppl):90;Abstract Not Available.

Grothey A et al. Randomized phase II trial of capecitabine plus irinotecan (CapIri) vs capecitabine plus oxaliplatin (CapOx) as first-line therapy of advanced colorectal cancer (ACRC). Proc ASCO 2003;Abstract 1022.

Hoff PM et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;22(11):2078-83. Abstract

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Kim JS et al. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54(2):403-8. Abstract

Patt YZ et al. Capecitabine plus irinotecan: A highly active first-line treatment for metastatic colorectal cancer (MCRC). ASCO Gastrointestinal Cancers Symposium 2004;Abstract 228.

Shields AF et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. Cancer 2004;100(3):531-7. Abstract